Clinical trials: Compliance, Treatment
Obese Adults
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
Background: Obesity affects 18.1% of adults in France and leads to numerous chronic complications as well as functional limitations (fatigability, dyspnea).
- Trial name
- ON-TRAC (NCT07903025)
- Testing
- Axomove Therapy, Standard multidisciplinary medical care
- Where
- 8 sites in France
- Volunteers
- 184 people
- Sponsor
- Axomove
Malaria
Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
This non-interventional qualitative study will examine factors that influence the adoption of a novel malaria treatment in Côte d'Ivoire, Ghana, and Rwanda.
- Trial name
- NCT07896746
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Adolescent Idiopathic Scoliosis
Green Sun Medical Dynamic Scoliosis Brace
This is a pilot study to collect preliminary short-term data concerning the safety and performance of the Green Sun Dynamic brace in a sample of subjects with adolescent idiopathic scoliosis who are currently being treated with a…
- Trial name
- GSM (NCT03641469)
- Testing
- Green Sun Dynamic Brace
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Green Sun medical
Multiple Myeloma, Solitary Plasmacytoma
MargheRITA (Remote Intelligence for Therapeutic Adherence)
It is essential to improve clinical efficiency and management of hematological and oncological patients treated on an outpatient basis.
- Conditions
- Multiple Myeloma, Solitary Plasmacytoma, Amyloidosis, Chronic Myeloid Leukemia
- Trial name
- MargheRITA (NCT05260203)
- Testing
- RITA (App)
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Advice Pharma Group srl
Chronic Kidney Diseases, Diabetes
KidneYou - Innovative Digital Therapy
The aim of the study is to assess the improvement of health in patients affected by CKD when they are exposed to non-pharmacological treatment strategies as nutritional program (NP), physical activity program (PA) and mindfulness…
- Conditions
- Chronic Kidney Diseases, Diabetes, Arterial Hypertension, Chronic Glomerulonephritis
- Trial name
- NCT05286632
- Testing
- KidneYou APP
- Where
- Italy
- Volunteers
- 210 people
- Sponsor
- Advice Pharma Group srl
Substance Use Disorders, Treatment Adherence and Compliance
RAE (Realize, Analyze, Engage)
The proposed study will evaluate the detection of digital biomarkers of stress, and drug craving in a population of individuals undergoing treatment for substance use disorder
- Trial name
- NCT05227339
- Testing
- RAE
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- ContinueYou, LLC
Treatment Adherence, Generalized Anxiety
Cerina-A Pilot Randomized Controlled Trial
The goal of this pilot Randomized Controlled Trial is twofold: 1) To learn about the feasibility and usefulness of a mobile application for generalised anxiety symptoms (Cerina); 2) To test the preliminary effects of Cerina in…
- Conditions
- Treatment Adherence, Generalized Anxiety, Treatment Adherence and Compliance
- Trial name
- Cerina (NCT06146530)
- Testing
- Treatment
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Cerina Therapeutics
Kidney Transplant; Complications, Liver Transplant; Complications
Medicine Adherence and Effects on Transplants With Pilloxa's Electronic Pillbox
Poor adherence to medication among patients with chronic diseases is a major problem. A patient group where the adherence to prescribed medications is extremely important are organ transplanted patients.
- Trial name
- NCT03848585
- Testing
- Pilloxa Pillbox, Non active Pilloxa Pillbox
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Pilloxa
Dyslipidemia, Hyperlipidemia
Rosuvastatin Adherence App Study in China
This is a randomized, two-arm, open label, Phase IV clinical trial to evaluate if the provision of a smart phone-based patient support tool prolongs the patient's rosuvastatin treatment duration.
- Trial name
- eHELP China (NCT02433288)
- Testing
- Smart phone based patient support tool, Control application: only for data collection
- Where
- 25 sites in China
- Volunteers
- 885 people
- Sponsor
- AstraZeneca
Schizophrenia, Mental Disorder
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
The purpose of this study is to determine the usability of the Medical Information Device #1 (MIND1) system in adults with schizophrenia who are treated with oral aripiprazole.
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02219009
- Testing
- MIND1 System
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Rheumatoid Arthritis
Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis
The aim of this study is to evaluate, at 6 months, the rate of patients whose adherence to injectable MTX remained strong or improved according to patient-reported outcome.
- Trial name
- APRim (NCT02897817)
- Where
- France
- Volunteers
- 471 people
- Sponsor
- Nordic Pharma SAS
Bipolar 1 Disorder, Schizophrenia
Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
The purpose of this study is to evaluate adherence to treatment with, and safety and tolerability of, the medical information device #1 (MIND1) system in subjects with Schizophrenia or Bipolar I Disorder who are currently treated…
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT01981811
- Testing
- Aripiprazole, Ingestible Event Marker (IEM)
- Where
- 12 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Coronary Artery Disease, Acute Coronary Syndrome
Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment
The objective of GIANT Study is to evaluate the clinical impact of genetic resistance to thienopyridine profile determination (CYP2C19 gene) and the clinical impact of compliance to an adjusted thienopyridine treatment on STEMI…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Genetic Resistance to Clopidogrel, Compliance to Thienopyridine Treatment
- Trial name
- GIANT (NCT01134380)
- Where
- 12 sites in France
- Volunteers
- 1,500 people
- Sponsor
- Biotronik France
Schizophrenia, Tranquilizing Agents
A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone.
- Conditions
- Schizophrenia, Tranquilizing Agents, Mental Disorders, Therapeutic Uses
- Trial name
- NCT00294008
- Testing
- Risperdal Consta
- Volunteers
- 230 people
- Sponsor
- Janssen Korea, Ltd., Korea
Bipolar 1 Disorder, Schizophrenia
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
- Trial name
- NCT02050854
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Human Immunodeficiency Virus Infection
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Both twice-a-day (BID) and once-a-day (QD) dosing are approved in Europe for the protease inhibitor lopinavir/ritonavir (LPV/r; Kaletra®).
- Trial name
- QD-Kapital (NCT01383005)
- Where
- 20 sites in Spain
- Volunteers
- 97 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Bipolar Disorders
Study of the Clinical Management of Bipolar Disease
This study is to provide reliable information on the management of bipolar disorders in real every day, clinical practice, to determine the clinical outcomes of such management and use of resources in relation to the disease, and…
- Trial name
- WAVE bd (NCT01062607)
- Where
- 213 sites in Austria, Belgium and 8 more
- Volunteers
- 2,965 people
- Sponsor
- AstraZeneca
Hypertension
To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension
The main goal of this study is to achieve a deeper knowledge of the adherence to antihypertensive drug treatment and to evaluate the quality of life in this population.
- Trial name
- ADHERENCE (NCT00944489)
- Where
- Argentina
- Volunteers
- 1,150 people
- Sponsor
- AstraZeneca
Schizophrenia
Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.
- Trial name
- SMS (NCT00873249)
- Where
- 25 sites in Spain
- Volunteers
- 339 people
- Sponsor
- AstraZeneca